204 related articles for article (PubMed ID: 20876793)
1. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer.
Kang BH; Siegelin MD; Plescia J; Raskett CM; Garlick DS; Dohi T; Lian JB; Stein GS; Languino LR; Altieri DC
Clin Cancer Res; 2010 Oct; 16(19):4779-88. PubMed ID: 20876793
[TBL] [Abstract][Full Text] [Related]
2. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease.
Kang BH; Tavecchio M; Goel HL; Hsieh CC; Garlick DS; Raskett CM; Lian JB; Stein GS; Languino LR; Altieri DC
Br J Cancer; 2011 Feb; 104(4):629-34. PubMed ID: 21285984
[TBL] [Abstract][Full Text] [Related]
3. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90.
Kang BH; Plescia J; Song HY; Meli M; Colombo G; Beebe K; Scroggins B; Neckers L; Altieri DC
J Clin Invest; 2009 Mar; 119(3):454-64. PubMed ID: 19229106
[TBL] [Abstract][Full Text] [Related]
5. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
He S; Zhang C; Shafi AA; Sequeira M; Acquaviva J; Friedland JC; Sang J; Smith DL; Weigel NL; Wada Y; Proia DA
Int J Oncol; 2013 Jan; 42(1):35-43. PubMed ID: 23152004
[TBL] [Abstract][Full Text] [Related]
6. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
Weber H; Valbuena JR; Barbhuiya MA; Stein S; Kunkel H; García P; Bizama C; Riquelme I; Espinoza JA; Kurtz SE; Tyner JW; Calderon JF; Corvalán AH; Grez M; Pandey A; Leal-Rojas P; Roa JC
Oncotarget; 2017 Apr; 8(16):26169-26184. PubMed ID: 28412732
[TBL] [Abstract][Full Text] [Related]
7. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
8. Heteronemin, a Marine Sesterterpenoid-Type Metabolite, Induces Apoptosis in Prostate LNcap Cells via Oxidative and ER Stress Combined with the Inhibition of Topoisomerase II and Hsp90.
Lee MG; Liu YC; Lee YL; El-Shazly M; Lai KH; Shih SP; Ke SC; Hong MC; Du YC; Yang JC; Sung PJ; Wen ZH; Lu MC
Mar Drugs; 2018 Jun; 16(6):. PubMed ID: 29890785
[TBL] [Abstract][Full Text] [Related]
9. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.
Lamoureux F; Thomas C; Yin MJ; Kuruma H; Fazli L; Gleave ME; Zoubeidi A
Clin Cancer Res; 2011 Apr; 17(8):2301-13. PubMed ID: 21349995
[TBL] [Abstract][Full Text] [Related]
10. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.
Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G
Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743
[TBL] [Abstract][Full Text] [Related]
11. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer.
Leav I; Plescia J; Goel HL; Li J; Jiang Z; Cohen RJ; Languino LR; Altieri DC
Am J Pathol; 2010 Jan; 176(1):393-401. PubMed ID: 19948822
[TBL] [Abstract][Full Text] [Related]
12. Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.
O'Malley KJ; Langmann G; Ai J; Ramos-Garcia R; Vessella RL; Wang Z
Prostate; 2012 Jul; 72(10):1117-23. PubMed ID: 22161776
[TBL] [Abstract][Full Text] [Related]
13. Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.
Le B; Powers GL; Tam YT; Schumacher N; Malinowski RL; Steinke L; Kwon G; Marker PC
PLoS One; 2017; 12(3):e0174658. PubMed ID: 28350865
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
15. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
[TBL] [Abstract][Full Text] [Related]
16. The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.
Moses MA; Henry EC; Ricke WA; Gasiewicz TA
Cancer Prev Res (Phila); 2015 Mar; 8(3):249-57. PubMed ID: 25604133
[TBL] [Abstract][Full Text] [Related]
17. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model.
Williams CR; Tabios R; Linehan WM; Neckers L
J Urol; 2007 Oct; 178(4 Pt 1):1528-32. PubMed ID: 17707057
[TBL] [Abstract][Full Text] [Related]
18. SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells.
Wang SX; Ju HQ; Liu KS; Zhang JX; Wang X; Xiang YF; Wang R; Liu JY; Liu QY; Xia M; Xing GW; Liu Z; Wang YF
Biosci Biotechnol Biochem; 2011; 75(8):1540-5. PubMed ID: 21821931
[TBL] [Abstract][Full Text] [Related]
19. Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.
Saturno G; Valenti M; De Haven Brandon A; Thomas GV; Eccles S; Clarke PA; Workman P
Oncotarget; 2013 Aug; 4(8):1185-98. PubMed ID: 23852390
[TBL] [Abstract][Full Text] [Related]
20. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
